Get your daily dose of health and medicine every weekday with STAT’s free newsletter Morning Rounds. Sign up here.
Good morning. In a search for silver linings yesterday, I found this: I can finally spell the word “diarrhea” confidently! The latest on cyclosporiasis, measles, and more below.
Mostly wins for peptides at FDA advisory meeting
After two days of meetings last week, an FDA advisory panel has recommended to ease access to six out of seven peptides it considered. In narrow, contested votes, panelists voted to allow compounding pharmacies to manufacture the peptides, despite scant evidence on safety and efficacy. Each peptide has a specific indication, but if the recommendations become policy, they would effectively become available for a range of conditions.
The FDA does not need to follow the panel’s recommendations, and in fact, agency staffers said they were against easing access for any of the peptides. Normally, the final decision would be made by those same employees, but it’s possible that Trump administration leaders could overrule them. Read more from STAT’s Lizzy Lawrence on where the final votes landed and what comes next.
